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It is widely accepted that cancer results from the accumulation of
mutations in genes responsible for control of cell survival and cell
death. Genetic analysis of human tumours at presentation reveals a
striking degree of heterogeneity; tumours are never composed of
genetically identical cells, and no two tumours are alike (Fey and
Tobler, 1996). A recent review strongly supports the existence of
genetic instability, at both nucleotide and chromosome level, as
the driving force behind the accumulation of mutations in nearly
all solid tumours (Lengauer et al, 1998). This combination of
genetic instability and clonal expansion allows a process of selec-
tion to occur within a tumour, in which subclones with a survival
or growth advantage will come to predominate the tumour in time.
In recent years a broad range of tumour-associated antigens
(TAA), restricted by both class I and class II MHC molecules,
have been identified. This has been facilitated by techniques using
recombinant DNA technology, cellular immunology, and serolog-
ical screening with autologous antibodies. Human TAAs have
been identified in a variety of tumours and are likely to represent a
small proportion of potential antigens expressed. Such TAAs
include:
• Tumour-specific shared antigens such as members of the
MAGE family, encoded by normal, non-mutated genes, though
restricted in expression to tumours and immune privilege sites
such as the testis.
• Tissue-specific differentiation antigens such as tyrosinase.
• Tumour specific antigens generated by point mutations or
translocations.
• Ubiquitous antigens with a significant degree of over-
expression in tumours (Rosenberg, 1999).
There is currently little consensus on the extent to which tumour
and host immune system interact. It is becoming clear that the
immune response has evolved to be activated by recognition 
of pathogen-associated molecular patterns (PAMPs) within an
inflammatory context (Janeway et al, 1996). It is difficult to
envisage how an adaptive anti-tumour immune response would be
initiated. The majority of human tumours do not express PAMPs
and tumorigenesis is initially an innocuous extension of self.
Moreover, examination of patients with more advanced tumours
shows little evidence of an effective host response. These consid-
erations have led many immunologists to conclude that while
tumours may be antigenic, they are unlikely to be immunogenic.
As such, an immunological ignorance or a progressive tolerance
would be expected to occur during the natural history of a tumour.
Interestingly, several studies have identified mechanisms by
which tumour cells may potentially evade an immune response.
This review will examine the pattern and frequency with which
‘immune escape’ mechanisms occur in human tumours. The
nature of each immune escape mechanism will be assessed in the
context of known or potential interactions between tumour and
host immune system. A microevolutionary model of tumour
development involving escape from immunological control will
then be presented. The implications of this model for the develop-
ment of clinical immunotherapeutic strategies and our under-
standing of current in vivo models of tumour immunotherapy will
be discussed.
Anti-tumour immunity and immune escape
mechanisms
The identification of a broad range of TAAs provides the basis for
specific rejection of tumours by the cell-mediated arm of the adap-
tive immune system. Many studies identifying TAAs have used
tumour-specific CD8+ and CD4+ T cell clones raised from the
autologous host (Boon, 1992; Cox et al, 1994). While these studies
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patients, they provide no evidence for a functional role of these T
cells in anti-tumour immune responses. However, studies have
identified TAAs by use of circulating tumour-specific antibodies
in the autologous host; such TAAs may also be recognized by CTL
(Chen et al, 1997). The identification of a variety of circulating
tumour-specific antibodies in the serum of cancer patients suggests
that tumours are capable of eliciting multiple specific immune
responses (Sahin et al, 1995).
The presence of tumour-infiltrating lymphocytes (TIL) has been
demonstrated in biopsies of a variety of histological types of
tumour. Isolation and characterization of TIL has shown that they
constitute both CD4+ and CD8+ ab T cells that may recognize
autologous tumours and tumour cell lines in assays of cytotoxicity
and cytokine secretion. However, the nature of TIL depends on the
tumour type from which they were derived. Melanoma-derived
TIL exert a greater anti-tumour effect than those derived from
breast or colon cancer biopsies (Yannelli et al, 1996). Early studies
using MHC-peptide tetramer staining showed high numbers of
antigen-experienced CTL specific for Melan-A in metastatic
lymph nodes of melanoma patients. These CTL were capable of
clonal expansion and autologous tumour lysis (Romero et al,
1998).
The classical MHC class I pathway functions to present largely
endogenous peptides to CTL, and is understood to restrict the anti-
tumour T cell response. Alteration of MHC class I expression is a
widespread occurrence in neoplasia, though irregular in pattern
(Garrido et al, 1993). It may take the form of a complete loss of
MHC class I expression, or more frequently, a partial MHC class I
expression involving loss of haplotypes, loci, or individual alleles.
Reduction in expression of the MHC class I element which
restricts tumour-specific CTL cytotoxicity may reflect a process of
immune escape during the development of the tumour.
MHC class I downregulation may result from structural defects
in MHC genes, downregulation of MHC gene transcription,
defects in b2-microglobulin (b2m) synthesis, or defects in MHC
molecule assembly. Peptide fragments are usually generated by the
multicatalytic proteosome complex, particularly LMP-2 and -7
subunits. These subunits may alter the pattern of protein cleavage
within the proteosome, favouring the generation of immunogenic
peptides (Driscoll et al, 1993). Peptides are subsequently trans-
ported into the endoplasmic reticulum (ER) by a complex
consisting of transporters associated with antigen presentation,
TAP1 and TAP2 subunits. Within the ER, peptide binds to the
heavy chain and b2 m to form a stable peptide-MHC molecule
complex (York and Rock, 1996). It is known that defects in this
antigen processing and presentation machinery impair the
assembly of class I MHC molecules, and thus decrease their cell
surface expression and stability (Ljunggren et al, 1990). Analysis
of small cell lung carcinoma (Restifo et al, 1993), hepatocellular
carcinoma (Kurokohchi et al, 1996), melanoma (Maeurer et al,
1996) and renal cell carcinoma (Seliger et al, 1996a; 1996b) lines
has revealed a heterogeneous downregulation of LMP-2, LMP-7,
TAP-1 and TAP-2.
Natural killer (NK) cell surveillance is believed to participate 
in anti-tumour immunity. NK cell cytotoxicity is controlled by a
balance of triggering and inhibitory signals. Inhibitory signals are
received through engagement of killer inhibitory receptors (KIRs)
with specific MHC class I molecules on target cells (Lanier, 1998).
Reduction in MHC class I expression to decrease susceptibility to
CTL lysis may therefore increase susceptibility to NK cell cytotox-
icity. Alterations in MHC class I expression for purpose of immune
escape would be expected to reflect this dual pressure. This is
supported by data from cervical cancer patients which demonstrate
that downregultion of MHC class I expression is accompanied by a
relative over-representation of alleles specific for the individual
patient KIRs (Keating et al, 1995). Immune escape from NK cell
cytotoxicity is concordant with the frequent loss of MHC class I
haplotype, locus, or allele expression, rather than the complete loss
of MHC class I expression (Garrido et al, 1997).
CTL and NK cells induce apoptosis in target cells by activation
of intracellular caspase cascades. Expression of Fas ligand (FasL)
or membrane TNF allows direct ligation of Fas or TNF receptors,
constitutively expressed on the surface of most cell types, and
transduction of a signal which activates intracellular caspases.
Degranulation of CTL and NK cells leads to perforin-mediated
pore formation and cytoplasmic introduction of granzyme B, a
protein capable of direct activation of intracellular caspase-8
(Berke, 1995; Medema et al, 1997). Tumours are frequently
observed to lose sensitivity to apoptosis. Blockade of the intra-
cellular transduction of apoptotic signals has been demonstrated to
occur in melanoma by expression of FLICE-like inhibitory
proteins that inhibit activation of caspase-8 (Irmler et al, 1997).
Overexpression of the anti-apoptotic proteins Bcl-2 or Bcl-XL has
been observed in many tumours, including head and neck tumours
(Pena et al, 1999), gastric carcinoma (Aizawa et al, 1999), and
oesophageal carcinoma (Torzewski et al, 1998). Alteration of
sphingomyelinase activation and subsequent ceramide generation
has been suggested to function in preventing TNF-mediated cyto-
toxicity in breast tumours (Cai et al, 1997).
Such adaptations are intrinsic to tumour growth. However,
tumours also exhibit mechanisms to block the initial extracellular
signals provided by T or NK cells for the induction of apoptosis.
The genomic amplification and secretion of decoy receptor 3
(DcR3) in colon, lung, breast and gastric tumours was recently
described (Pitti et al, 1998). DcR3 specifically binds and blocks
the function of FasL. The secretion of soluble Fas (sFas) has also
been observed in hepatocellular carcinoma (Jodo et al, 1998). In a
similar fashion to DcR3, sFas binds and blocks the function of
FasL (Cheng et al, 1994), thus inhibiting T cell and NK cell 
cytotoxicity. Such mechanisms may allow effective escape from
immunological control.
There is a large body of evidence to support the view that stim-
ulation of apoptotic cell death by the Fas-FasL pathway may also
be reversed in the host-tumour immune interaction. The expres-
sion of FasL has been identified in melanoma (Hahne et al, 1996),
colon carcinoma (O’Connell et al, 1998), hepatocellular carcinoma
(Strand et al, 1996), gastric adenocarcinoma (Bennett et al, 1999)
and lung carcinoma (Niehans et al, 1997). In a process termed the
‘Fas counterattack’, it is suggested that tumour cells might be able
to promote the death of activated tumour-specific T cells or NK
cells within the cancer microenvironment, thus creating a tumour-
specific window of tolerance. Such tumours frequently lose
expression of Fas (Strand et al, 1996), ostensibly to avoid the
induction of suicidal or fratricidal cell death, though insensitivity
to apoptosis might allow coexpression of Fas and Fas L. The
development of surface FasL expression by a tumour cell would
constitute an effective mechanism of immune escape.
Tumours have been observed to secrete a range of cytokines
with the potential to inhibit activation of, downregulate or subvert
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cytokines into the immediate microenvironment may reflect a
process of immune escape. TGF-b is a potent immunosuppressive
factor, and affects activation, proliferation and differentiation of
both innate and adaptive immune cells (Chouaib et al, 1997).
Studies have identified expression and secretion of TGF-b in
bladder tumours (Eder et al, 1997), gastric carcinoma (Morisaki et
al, 1996), breast and hepatocellular carcinoma (Vanky et al, 1997).
Both TGF-b and IL-10 are understood to play a role in shifting the
Th1-Th2 balance toward Th2, thus inhibiting the cell-mediated
immunity believed to be responsible for tumour rejection (Maeda
and Shiraishi, 1996). Secretion of IL-10 has been observed in renal
cell carcinoma, colon carcinoma, melanoma and neuroblastoma
(Gastl et al, 1993). Studies have demonstrated that a shift toward a
Th2 cytokine profile can inhibit an otherwise effective anti-tumour
immune response (Hu et al, 1998). Furthermore, it has been
demonstrated that local IL-10 secretion by tumours can confer a
complete resistance to CTL lysis (Matsuda et al, 1994).
Adhesive interactions between immune cells and target cells 
are critical to the processes of recognition and cytotoxicity.
Alterations in the expression and function of intercellular adhesion
molecules are frequently observed in tumours. The capacity of a
tumour cell to inhibit adhesive interactions with immune effector
cells may represent a potentially effective mechanism of immune
escape. It is becoming clear that the mucosal immune response is
mediated by a subset of T cells expressing aEb7-integrin. Such T
cells are restricted by adhesion through aEb7-integrin to E-
cadherin expressing epithelial target cells (Karecla et al, 1996).
The loss of E-cadherin expression on epithelioid tumours would
allow effective escape from immunological control by aEb7-
integrin-dependent T cells. Studies in pancreatic cancer have
demonstrated loss of E-cadherin expression after infiltration with
aEb7-integrin-expressing T cells, associated with the progression
of a well differentiated tumour to a poorly differentiated and more
invasive phenotype (Ademmer et al, 1998). it is understood that
loss of E-cadherin expression leads to a breakdown in cell–cell
adhesion and activation of several signalling pathways
(Christofori and Semb, 1999). As such, loss of E-cadherin expres-
sion for purpose of immune escape may incidentally lead to the
development of an aggressive, pro-metastatic tumour phenotype.
Several epitheloid tumours including bladder, breast, ovarian
and colorectal carcinomas are known to alter their expression
pattern of large mucin molecules such as MUC-1. Such molecules
project from the cell surface and may interfere with normal inter-
cellular adhesion by steric blockade of the molecular interactions
(Taylor Papadimitriou and Finn, 1997). Several groups have
shown that the expression of MUC-1 can protect tumour cells
from cytolysis by CTL (van de Welvankemenade et al, 1993) and
NK cells (Zhang et al, 1997). It has also been reported that MUC-
1 can inhibit proliferation and induce an anergic state in T cells
(Agrawal et al, 1998). Such interactions suggest that MUC-1
expression may constitute another effective mechanism of
immune escape.
The nature of these adaptations, when considered together,
provides compelling evidence for a process of escape from
immunological control in many common human tumours. This is
supported by functional analysis of TAA-specific elements of the
adaptive immune system in patients with advanced cancer. One
such study used MHC-peptide tetramer staining to isolate circu-
lating CD8+T cell populations specific for MART-1 and tyrosinase
TAAs from melanoma patients. It was demonstrated that TAA-
specific CTL have been rendered functionally unresponsive in
vivo; isolated CTL were incapable of antigen-specific target cell
lysis or cytokine production (Lee et al, 1999).
Model of immune selection in neoplasia
Complex adaptations exhibited by tumours are unlikely to be
developed at random. The combination of genetic instability and
clonal expansion allows a gradual process of microevolution to
occur, in which subclones with a survival or growth advantage
come to predominate the tumour. This requires selective pressure.
Competition for space, ability to recruit neovasculature and the
ability to detach from neighbouring cells may all represent early
selective pressures. Microevolutionary tumour development has
long been recognized in the field of chemotherapy for neoplasia.
Following drug-induced regression, approximately 30% of
tumours recur in a form resistant to the chemotherapeutic agent
(Young, 1989). This process is termed acquired drug resistance.
It has been established that a variety of immune escape mecha-
nisms are commonly expressed by tumours of diverse histological
type. Although widely acknowledged, the scientific community
has not focused on the implication for immunological involvement
in tumour development. Mechanisms of immune escape are
unlikely to occur spontaneously in such a consistent fashion.
Rather, it may be argued that immune escape mechanisms reflect a
process of microevolution following a period of sustained selec-
tive pressure by an anti-tumour host immune response.
It is unclear how the immune system would survey for
neoplasia. Activation of an adaptive response would require
processing and presentation of tumour antigen to tumour-specific
T cells by professional APCs. The majority of human tumours do
not express PAMPs. Moreover, the initial period of tumour growth
is an innocuous extension of self and generally not associated with
any ‘danger’ signals (Fuchs and Matzinger, 1996). Thus, tumours
would not be expected to stimulate APC maturation and the
activation of an anti-tumour adaptive response. The host would
remain immunologically ignorant, and thus completely tolerant to
the tumour, over the initial years of tumour development. A recent
study showed this type of immunological ignorance to solid
tumours in vivo (Ochsenbein et al, 1999). In this study, tumour
growth correlated with the failure of tumour antigen to reach local
lymph nodes and the absence of primed CTL. Importantly though,
this study demonstrated that established solid tumours could be
rejected by effective induction of an anti-tumour T cell response.
Progressive tumour growth may eventually generate signals
capable of stimulating an adaptive response. An inflammatory
reaction commonly occurs within the tumour microenvironment
(Hakansson et al, 1997). Ischaemia and oxidative stress within the
tumour microenvironment may lead to the upregulation of heat
shock protein expression, identified as potential danger signals
(Multhoff et al, 1995). Necrotic cell death, demonstrated to be
highly immunogenic, frequently occurs at the tumour core
(Melcher et al, 1998). It is reasonable to expect that such signals
will activate tumour-resident professional APCs and allow presen-
tation of TAAs to T cells (Gallucci et al, 1999). This is supported
by studies that have demonstrated activation of the immune
system by heat shock proteins expressed by tumours (Todryk et al,
1999) and the constitutive processing and presentation of tumour
antigen in lymph nodes draining tumour sites (Marzo et al, 1999).
1902 SJ Pettit et al
British Journal of Cancer (2000) 82(12), 1900–1906 © 2000 Cancer Research CampaignActivation of an anti-tumour immune response would place a
novel selective pressure on established tumours. Certain subclones
within the heterogeneous tumour may express gene products or
exhibit characteristics that reduce the susceptibility of that subclone
to an immune response. The pressure of an immune response will
place such subclones at a selective advantage over other subclones
within the tumour. Thus, subclones resistant to an immune response
will gradually come to predominate within the tumour. Adaptations
of great complexity may arise by a series of single selective events,
directed by nonrandom survival, in a deceptively simple process
termed cumulative selection (Dawkins, 1988). This provides a
rational explanation for the development of immune escape mecha-
nisms. Tumours subjected to immune selection would be expected
to exhibit a range of immune escape adaptations of considerable
sophistication at all levels of host–tumour immune interaction. This
has been demonstrated in a wide variety of human tumours.
In summary, the process of immune selection may be considered
to occur in three non-discrete phases, as depicted in Figure 1.
During the first phase, initiation, proliferation and diversification
of tumour occurs against a background of immune ignorance. The
second phase is entered where an anti-tumour immune response is
activated. Consequent immune selection pressure allows a process
of microevolution to lead to the gradual acquisition of adaptations
that permit immune evasion. The third phase of immune escape is
reached when tumour cells acquire sufficient adaptations to allow
proliferation unchecked by immunological control.
Evidence for a process of immune selection
It is difficult to provide direct evidence to support a process of
immune selection and the microevolutionary development of
immune escape adaptations. However, it has been possible to
demonstrate the progressive nature of development of certain
adaptations that may function in immune escape. While such adap-
tations only constitute circumstantial evidence of immune selec-
tion, their pattern of acquisition is instructive in examining how
the process of immune selection might function in vivo.
Several studies have elegantly demonstrated the gradual nature
of MHC class I loss with tumour progression. This process was
illustrated in a study showing progressive allelic MHC class I loss
in metastases of a single melanoma patient examined 5 years apart
(Lehmann et al, 1995). Further evidence for this type of process
was provided in a study of cervical carcinoma patients showing
MHC class I downregulation in metastases compared with 
the primary tumour (Cromme et al, 1994). Interestingly, a recent
review of alteration of TAP-1 expression in tumour biopsies in situ
identified an association between the severity of abnormalities in
antigen processing machinery and the progression of neoplastic
disease (Seliger et al, 1997). Progressive downregulation of LMP
and TAP protein expression has been demonstrated in the metas-
tases of patients with renal cell carcinoma (Seliger et al, 1996a;
1996b). Progressive acquisition of immune escape mechanisms is
consistent with the proposal of a gradual process of immune selec-
tion during the natural history of the tumour.
There is little experimental evidence on the extent of immune
involvement in the development of neoplasia. Such evidence is
difficult to obtain in humans; the period of interest is in the early
asymptomatic phase of tumour development. Murine models of
immune involvement in neoplasia have frequently focused on
transplanted tumours. However, two studies have investigated
immune involvement in the ‘natural’ development of neoplasia.
They compared the immunogenicity of induced tumours from
immunodeficient mice and congenic mice with a normal immune
system. The first study used athymic nude BALB/c mice as a
model of immunodeficiency (Svane et al, 1996), the second study
used C.B-17 mice with severe combined immune deficiency
(SCID) (Engel et al, 1997). In both studies, mice were treated with
a potent carcinogen, MCA, and any tumours which developed
were recovered. After brief propagation in vitro, tumours were
transplanted into syngeneic immunocompetent mice. Tumours that
developed in immunodeficient mice were shown to be rejected at a
significantly greater rate than those developed in normal mice.
These studies demonstrate that interaction with the acquired arm
of the host immune system during the initiation and development
of neoplasia has the effect of decreasing the immunogenicity of
resulting tumours, reflecting a process of immune selection.
It must be stressed that while immune escape adaptations in
human tumours can be viewed in the context of immune selection
in the development of neoplasia, they do not provide firm evidence
that immune selection takes place in vivo. Indeed, such adapta-
tions may simply be markers of the process of dedifferentiation
that accompanies tumour development and reflect the reacquisi-
tion of a ‘stem cell’ type phenotype. As such, these features may
aid evasion of an immune response, without necessarily being
selected by it. Further experimental evidence is required to allow
this model of immune selection to be conclusively accepted or
rejected. However, it is interesting to examine the implications of a
hypothetical process of immune selection.
Implications of immune selection
The process of immune selection in neoplasia and consequent
development of immune escape mechanisms are consistent with
the observation that there is little evidence of a clinically effective
immune response in the majority of progressive tumours.
However, an acceptance that induction of an anti-tumour immune
response may lead to a process of immune selection has serious
implications for the development and improvement of immuno-
therapeutic strategies.
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Initiation, proliferation
and diversification
Microevolution by continuing
diversification and selection of
clones which are resistant to
a range of immune effector
mechanisms
Escape and unchecked proliferation of
cancer cells which are resistant to any
immune attack
Figure 1 Scheme of immune selection in the development of cancer. The
first phase involves initiation, early proliferation and diversification of a
neoplasm. The second phase involves gradual microevolution of the
neoplasm under the pressure of immune selection. The third phase involves
escape of the neoplasm from immunological control and unchecked
progression.1904 SJ Pettit et al
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The success of immunotherapeutic strategies may depend on the
natural history of the tumour. Tumours of higher stage may have
been subjected to a greater degree of immune selection, and are
thus more likely to be adapted to evade the very immune response
that such therapeutic strategies attempt to induce. Early tumours
are less likely to have been subjected to immune selection pres-
sure. A recent study showed that small solid tumour fragments are
ignored by the immune system, but may be rejected by an inter-
vention that results in the induction of an anti-tumour immune
response (Ochsenbein et al, 1999). Another study demonstrated
that antigenic cancer cells may grow progressively in immuno-
competent mice for 30 days with no evidence of T cell exhaustion
or systemic anergy (Wick et al, 1997). These studies suggest
immunotherapeutic strategies may be successful, when applied
early in the natural history of the tumour.
It is well established that intravesical instillation of bacillus
Calmette-Guerin (BCG) offers an effective therapeutic approach
for treatment of superficial transitional cell carcinoma (TCC) of
the urinary bladder (Alexandroff et al, 1999). The considerable
success in the use of BCG therapy may be due, in part, to the early
stage at which these tumours are diagnosed. Superficial TCC is
commonly associated with symptoms such as haematuria that tend
patients toward an early presentation. Moreover, patients with a
history of superficial TCC are screened by regular cystoscopy for
tumour recurrence. The early use of BCG therapy means that any
immune component to the BCG-mediated anti-tumour response
will be directed against a tumour which is unlikely to have been
subjected to extensive immune selection.
Immunotherapeutic strategies might be improved by simulta-
neous efforts to reduce the genetic instability of tumours or to
reduce the clonal expansion that allows fixation of genetic changes
in the tumour cell progeny. This might be achieved by therapeutic
modalities that exert a direct anti-proliferative effect or that inhibit
proliferation through mechanisms such as inhibition of angiogen-
esis. Interestingly, it has been demonstrated that BCG exerts an
anti-proliferative effect on several TCC lines in vitro (Jackson et
al, 1994), and may induce the release of anti-angiogenic
chemokines such as IP-10 upon intravesical instillation (Poppas et
al, 1998). The real attraction of BCG therapy may be the highly
complex and multifactorial anti-tumour response that is induced.
This response involves elements of specific and non-specific anti-
tumour immunity combined with direct cytotoxic and cytostatic
effects. It is reasonable to propose that the non-specific action of
BCG may prevent immune selection resulting from the tumour-
specific actions of BCG.
The process of immune selection also provides an explanation
for the frequent observation that promising immunotherapeutic
strategies developed in murine models of cancer tend to translate
poorly into human clinical trials. Murine models of cancer are
frequently based on the inoculation of a mouse with a tumour cell
line, previously propagated in vitro. The use of cell lines has a
number of drawbacks. Cell lines are commonly derived from
advanced tumours and may have already been subjected to a
degree of immune selection in vivo. Moreover, cell lines retain
the genetic instability of the parent tumour and may lose parental
adaptations during in vitro propagation. Cell lines are introduced
in large numbers, typically greater than 106 cells, and thus present
an unnaturally homogenous tumour burden to the immune system
at first encounter. Such tumours lack the long period of develop-
ment from the point of initiation at single-cell level, in which
host-tumour immune interactions would be expected to develop.
For these reasons, promising immunotherapeutic strategies devel-
oped in murine models of cancer may only reflect the inherent
susceptibility of certain cell lines within the chosen experimental
system.
CONCLUSION
Immune evasion mechanisms have now been identified in the
majority of common human tumours. These provide compelling
evidence for the existence of selective pressure by the immune
system, and thus for the initial existence of an anti-tumour immune
response. This is supported by recent murine models of immune
involvement in neoplastic development. Prolonged selective pres-
sure without complete clearance might eventually result in the
development of adaptations that allow a tumour to escape any
effective immune response. This model concurs with the clinical
observation that the immune system appears ineffective in the
control of progressive cancer. Further work is clearly required to
determine the nature of signals that may mediate activation of an
immune response during neoplastic development. However, an
understanding that tumours may have undergone a process of
immune selection prior to clinical presentation has serious impli-
cations for the development and application of immunotherapeutic
strategies.
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